reports
Sartorius Stedim Biotech publishes unaudited first quarter results for...
Sartorius Stedim Biotech SA / Key word(s): Quarter Results Sartorius Stedim Biotech publishes unaudited first quarter results for 2024 18-Apr-2024 / 07:02 CET/CEST Aubagne, France | April 18, 2024 Sartorius Stedim Biotech publishes unaudited first quarter results for 2024 Sales revenue of 667 million euros, in constant currencies1 - 9.4 percent organically1and - 6.7 percent including acquisitions2(reported: - 8.2 percent) Order intake up 13.9 percent to 676 million euros (reported: 12.5 percent) with significant growth in recurring business, while demand from China remains we...
EQS-News: Sartorius: Ergebnisse des 1. Quartals im Rahmen der Erwartun...
EQS-News: SARTORIUS AG / Schlagwort(e): Quartalsergebnis Sartorius: Ergebnisse des 1. Quartals im Rahmen der Erwartungen; Wiederholgeschäft mit deutlichem Auftragswachstum; Nachfrage aus China weiter schwach; Ausblick für Gesamtjahr bestätigt (News mit Zusatzmaterial) 18.04.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Göttingen, 18. April 2024 Sartorius: Ergebnisse des 1. Quartals im Rahmen der Erwartungen; Wiederholgeschäft mit deutlichem Auftragswachstum; Nachfrage aus China weiter schwach; Ausblick für Gesamtjahr ...
EQS-News: Sartorius: First quarter results in line with expectations; ...
EQS-News: SARTORIUS AG / Key word(s): Quarter Results Sartorius: First quarter results in line with expectations; recurring business with significant order growth; demand from China remains weak; outlook for full year confirmed (news with additional features) 18.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Göttingen, April 18, 2024 Sartorius: First quarter results in line with expectations; recurring business with significant order growth; demand from China remains weak; outlook for full year confirmed Inventory reduc...
Biophytis announces new Scientific Advisory Board for its phase 2 OBA ...
Biophytis / Key word(s): Miscellaneous Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity 18-Apr-2024 / 07:02 CET/CEST Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity IND to be filed with the FDA in the coming weeks Paris (France) and Cambridge (Massachusetts, USA), April 18, 2024 – 07:00am CET – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-relat...
Biophytis annonce la création d'un Conseil Scientifique pour son étude...
Biophytis / Mot-clé(s) : Autres Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité 18-Avr-2024 / 07:02 CET/CEST Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité Dépôt d’IND auprès de la FDA dans les prochaines semaines Paris, France, Cambridge (Massachusetts, États-Unis), 18 avril 2024 – 7h00 – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), («Biophytis» ou la «Société»), une société de biotechnologie au stade clinique spécialisée dans le dév...
Journée des marchés des capitaux: Mobimo donne un aperçu approfondi de...
Mobimo Holding AG / Mot-clé(s) : Conférence/Immeubles Journée des marchés des capitaux: Mobimo donne un aperçu approfondi de ses projets clés et du pipeline de projets 18.04.2024 / 07:00 CET/CEST Communiqué de presse Journée des marchés des capitaux: Mobimo donne un aperçu approfondi de ses projets clés et du pipeline de projets Lucerne, le 18 avril 2024 – Mobimo accueille aujourd’hui à Zurich les investisseurs, les analystes, les représentants des bailleurs de fonds ainsi que les journalistes à l’occasion de la Journée des marchés des capitaux. A cette occasion, les six...
Kapitalmarkttag: Mobimo gibt vertieften Einblick in Schlüsselprojekte ...
Mobimo Holding AG / Schlagwort(e): Konferenz/Immobilien Kapitalmarkttag: Mobimo gibt vertieften Einblick in Schlüsselprojekte und Pipeline 18.04.2024 / 07:00 CET/CEST Medienmitteilung Kapitalmarkttag: Mobimo gibt vertieften Einblick in Schlüsselprojekte und Pipeline Luzern, 18. April 2024 – Mobimo begrüsst heute Investoren, Analysten, Vertreter von Kreditgebern sowie Medienschaffende in Zürich zum Kapitalmarkttag. Das sechsköpfige Management gibt dabei einen vertieften Einblick in wichtige Projekte sowie in die Projektpipeline. Einleitend rekapituliert Daniel Ducrey, CE...
Capital Markets Day: Mobimo offers deeper insights into key projects a...
Mobimo Holding AG / Key word(s): Conference/Real Estate Capital Markets Day: Mobimo offers deeper insights into key projects and pipeline 18.04.2024 / 07:00 CET/CEST Press release Capital Markets Day: Mobimo offers deeper insights into key projects and pipeline Lucerne, 18 April 2024 – Mobimo is welcoming investors, analysts, representatives of lenders and members of the media to its Capital Markets Day in Zurich today. The company’s six-member Executive Board will provide deeper insights into key projects and the project pipeline. To begin the event, Daniel Ducrey, C...
Sartorius Stedim Biotech publie ses résultats non audités pour le prem...
Sartorius Stedim Biotech SA / Mot-clé(s) : Résultat trimestriel Sartorius Stedim Biotech publie ses résultats non audités pour le premier trimestre 2024 18-Avr-2024 / 07:02 CET/CEST Aubagne, France | 18 avril 2024 Sartorius Stedim Biotech publie ses résultats non audités pour le premier trimestre 2024 Chiffre d’affaires à 667 millions d’euros, soit une baisse organique de 9,4 % à taux de change constant1 et une baisse de 6,7 % à taux de change constant en tenant compte des acquisitions2(baisse déclarée : - 8,2 %) Augmentation des prises de commandes de 13,9 % à 676 millions d...
Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release D...
Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details BRENTWOOD, Tenn., April 18, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2024 results before the market opens on Tuesday, May 7, 2024, to be followed by a conference call at 8:30 a.m. (Eastern Time). You can join the call as follows: Dial in number for live access: 1-877-451-6152 (domestic), 1-201-389-0879 (international)...
- Pierre FerraguÊ
Ensari Deri Gida Sanayi Ve Ticaret A S: 1 director
A director at Ensari Deri Gida Sanayi Ve Ticaret A S sold 4,400,000 shares at 30.780TRY and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
Salesforce Inc: 4 directors
A director at Salesforce Inc sold after exercising options 5,864 shares at 274.773USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Cencora Inc: 2 directors
A director at Cencora Inc sold/sold after exercising options 57,564 shares at 235.090USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
Belysse Group N.V.: 1 director
A director at Belysse Group N.V. bought 35,786 shares at 0.920EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Coop Pank unaudited financial results for Q1 2024
Coop Pank unaudited financial results for Q1 2024 By the end of the Q1 2024, Coop Pank had 189,000 customers, increased by 7,000 customers in the quarter (+4%) and by 34,000 in the year (+22%). The bank had 84,400 active customers, increased by 2,400 (+3%) in the quarter and by 14,300 (+20%) in the year. In Q1 2024, volume of deposits in Coop Pank decreased by 29 million euros (-2%), reaching total of 1.69 billion euros. Deposits from private clients increasing by 11 million euros: demand deposits increased by 8 million euros and term deposits increased by 3 million euros. Deposits from d...
Coop Pank 2024. aasta I kvartali auditeerimata majandustulemused
Coop Pank 2024. aasta I kvartali auditeerimata majandustulemused 2024. aasta I kvartali lõpu seisuga oli Coop Pangal 189 000 klienti, klientide arv kasvas kvartaliga 7000 kliendi võrra (+4%) ja aastaga 34 000 võrra (+22%). Aktiivselt arveldavaid kliente oli 84 400, kvartaliga kasvas aktiivselt arveldavate klientide arv 2400 võrra (+3%) ja aastaga 14 300 (+20%). Coop Panga hoiuste maht kahanes 2024. aasta I kvartalis 29 miljoni euro võrra (-2%), ulatudes 1,69 miljardi euroni. Eraklientide hoiuste portfell kasvas 11 miljoni euro võrra: nõudmiseni hoiused kasvasid 8 miljoni euro võrra ja tä...
Addex Therapeutics Reports Full Year 2023 Financial Results and Provid...
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 18, 2024 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug...
BioSenic S.A. : Transparency notifications received from François Rie...
BioSenic S.A. : Transparency notifications received from François Rieger PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, April 18, 2024, 7am CET – (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received transparency notifications from François Rieger. Details of the notifications can be found below and the full versions of the transparency declarations are available ...
BioSenic S.A. : Notifications de transparence reçues de la part de Fr...
BioSenic S.A. : Notifications de transparence reçues de la part de François Rieger COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes Mont-Saint-Guibert, Belgique, le 18 avril 2024 à 7h00 CET – (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto-immunes et inflammatoires graves et dans la thérapie cellulaire, annonce aujourd’hui la réception de notifications de transparence de François Rieger. Les détails des notifications peuvent être trou...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.